Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
July 30, 2022 at 14:40 PM EDT
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148 million in development and regulatory milestones.
